HOPX and gastric cancer: In gastric cancer(GC), butyrate acts as a GPR109A agonist and amplifies the cytotoxicity of CD8+ T cells and CAR-Claudin 18.2+ CD8+ T cells via the GPR109A/HOPX axis 134.